Indication
Beta Thalassemia Major
4 clinical trials
6 products
Clinical trial
an Open Label Trial of Evaluation of the Safety and Efficacy of Treatment With γ-globin Reactivated Autologous Hematopoietic Stem Cells in Subjects With β-thalassemia MajorStatus: Completed, Estimated PCD: 2023-10-15
Product
γ-globinClinical trial
Safety and Efficacy of Early-start Deferiprone Treatment in Infants and Young Children Newly Diagnosed With Transfusion-dependent Beta ThalassemiaStatus: Completed, Estimated PCD: 2020-09-29
Product
DeferiproneProduct
PlaceboClinical trial
An Open-label, Dose-escalation, Dose-finding, and Proof-of-concept Trial of SP-420 in Subjects With Transfusion-dependent β-thalassemiaStatus: Recruiting, Estimated PCD: 2024-07-01
Product
SP-420Clinical trial
A Phase I Clinical Trial for the Treatment of ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin GeneStatus: Active (not recruiting), Estimated PCD: 2024-07-01